Overview
Dermatology Regulatory Landscape
The regulatory environment for dermatology therapies involves specialized requirements from FDA Division of Dermatology and Dentistry, EMA Dermatology Working Party, PMDA Dermatology Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Biologic approval for dermatologic indications
- ✓ Topical drug safety assessment requirements
- ✓ Long-term safety study expectations for chronic therapies
- ✓ Patient-reported outcome (PRO) endpoint guidance
- ✓ Post-marketing safety monitoring for biologics
EMA Requirements
- ✓ Guideline on clinical investigation of psoriasis
- ✓ Atopic dermatitis clinical trial guidance
- ✓ Biosimilar requirements for dermatology biologics
- ✓ PSUR expectations for dermatology products
PMDA Requirements
- ✓ Japan-specific dermatology drug monitoring
- ✓ Biologic safety assessment requirements
- ✓ Post-marketing dermatology surveillance
ArcaScience Alignment
How ArcaScience Maps to Dermatology Requirements
Data Coverage
Dermatology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Dermatology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Dermatology and Dentistry and EMA Dermatology Working Party submission requirements.
Download
Get the Full Dermatology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources